Insider Buying: Akero Therapeutics, Inc. (NASDAQ:AKRO) Director Acquires 91,309 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham acquired 91,309 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average price of $44.75 per share, for a total transaction of $4,086,077.75. Following the completion of the transaction, the director now owns 1,091,309 shares in the company, valued at $48,836,077.75. The trade was a 9.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

G. Walmsley Graham also recently made the following trade(s):

• On Thursday, March 27th, G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock. The shares were acquired at an average cost of $43.55 per share, for a total transaction of $2,177,500.00.
• On Thursday, January 30th, G. Walmsley Graham purchased 200,000 shares of Akero Therapeutics stock. The shares were acquired at an average cost of $48.00 per share, for a total transaction of $9,600,000.00.

Akero Therapeutics Trading Down 7.3 %

Shares of AKRO traded down $3.10 during midday trading on Monday, hitting $39.62. The stock had a trading volume of 414,793 shares, compared to its average volume of 817,582. The business has a 50-day simple moving average of $46.01 and a two-hundred day simple moving average of $35.15. The firm has a market cap of $3.15 billion, a P/E ratio of -10.58 and a beta of -0.19. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, equities analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AKRO. Citigroup increased their target price on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Canaccord Genuity Group upped their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. HC Wainwright lifted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Finally, UBS Group upped their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics presently has an average rating of "Buy" and an average target price of $76.29.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in shares of Akero Therapeutics during the 4th quarter valued at $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Akero Therapeutics by 18.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company's stock valued at $1,988,000 after purchasing an additional 11,035 shares in the last quarter. Woodline Partners LP raised its stake in shares of Akero Therapeutics by 29.9% during the 4th quarter. Woodline Partners LP now owns 379,967 shares of the company's stock worth $10,571,000 after purchasing an additional 87,499 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Akero Therapeutics by 195.7% during the 4th quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock valued at $1,143,000 after buying an additional 27,200 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in shares of Akero Therapeutics by 43.3% during the 4th quarter. Two Sigma Investments LP now owns 127,320 shares of the company's stock valued at $3,542,000 after buying an additional 38,500 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.